Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 18;192(3):377-378.
doi: 10.1093/bjd/ljae465.

Targeting type 2 inflammation in bullous pemphigoid: dupilumab as a game changer opens new avenues

Luca Borradori  1 , Michael Hertl  2
Affiliations
Editorial

Targeting type 2 inflammation in bullous pemphigoid: dupilumab as a game changer opens new avenues

Luca Borradori et al. Br J Dermatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors have contributed to the European Academy of Dermatology and Venereology guideline for the management of bullous pemphigoid (BP). This commentary reflects the authors’ personal opinion. L.B. has received consultation fees from Sanofi, Regeneron and Argenx. M.H. has received consultation fees from Argenx, Sanofi, Novartis and Janssen-Cilag for work related to BP in addition to travel grants for congress participation from Sanofi, AbbVie and Almirall.

Comment on

  • Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series.
    Planella-Fontanillas N, Bosch-Amate X, Jiménez Antón A, Moreno-Vílchez C, Guerrero MG, Blanes Martínez MDM, Ballester Martínez MA, Bassas-Freixas P, Castaño Fernández JL, Estébanez Corrales A, Suarez Fernández R, Santos Alarcón S, Alonso AB, Torrent M, Ballano Ruiz A, Collantes Rodríguez C, España A, Fonseca Capdevila E, Faure IG, Hernández Fernández CP, Melgosa Ramos FJ, Spertino J, Zaragoza Ninet V, Armillas L, Bielsa I, Carrera C, Esquius Rafat M, Fulgencio Barbarin J, Fernandez Vela J, Lova Navarro M, Martín Callizo C, Martín-Sala S, Ojeda R, Amer MEP, Puigdollers AS, Pujol RM, Podlipnik S, Mascaró JM Jr, Curto-Barredo L. Planella-Fontanillas N, et al. Br J Dermatol. 2025 Feb 18;192(3):501-509. doi: 10.1093/bjd/ljae403. Br J Dermatol. 2025. PMID: 39418120

LinkOut - more resources